RxDoctor Payments Data

Daniel Finney

Physician Assistant · Gold Canyon, AZNPI 1225050156

Payments from drug & device makers

$4,378in general payments, 2019–2025

Across 253 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$755
  • AstraZeneca$688
  • GSK$419
  • Amgen$242
  • Boehringer Ingelheim$203
  • Exact Sciences$199
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,378 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$129,961
Medicare patients
552
Services billed
1,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$81,192
EliquisApixaban48$72,453
MounjaroTirzepatide37$56,803
JanuviaSitagliptin Phosphate22$33,865
JardianceEmpagliflozin25$27,641
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$23,531
MyrbetriqMirabegron16$18,136
XareltoRivaroxaban14$12,733
Breo ElliptaFluticasone/Vilanterol15$7,133
Levothyroxine Sodium293$3,263
Gabapentin151$3,202
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,938
Olmesartan Medoxomil89$2,692
Atorvastatin Calcium364$2,558
Albuterol Sulfate HfaAlbuterol Sulfate67$2,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$197$81,19251 claims
PfizerEliquis$161$72,45348 claims
Lilly USA, LLCMounjaro$180$56,80337 claims
MerckJanuvia$37$33,86522 claims
GSKTrelegy Ellipta, Breo Ellipta$419$30,66438 claims
Boehringer IngelheimJardiance$203$27,64125 claims
Astellas Pharma US IncMyrbetriq$127$18,13616 claims
Johnson & JohnsonXarelto$40$12,73314 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$91$3,263293 claims
AbbVieSynthroid$755$1,66217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Gold Canyon

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →